The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Open Access
- 1 April 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (7), 3751-3759
- https://doi.org/10.1182/blood-2007-07-102186
Abstract
The V617F activating point mutation in Jak2 is associated with a proportion of myeloproliferative disorders. In normal hematopoietic cells, Jak2 signals only when associated with a growth factor receptor, such as the erythropoietin receptor (EpoR). We sought to identify the molecular requirements for activation of Jak2V617F by introducing a point mutation in the FERM domain (Y114A), required for receptor binding. Whereas BaF3.EpoR cells are readily transformed by Jak2V617F to Epo independence, we found that the addition of the FERM domain mutation blocked transformation and the induction of reactive oxygen species. Further, while cells expressing Jak2V617F had constitutive activation of STAT5, cells expressing Jak2V617F/Y114A did not, suggesting that signaling is defective at a very proximal level. In addition, expression of the Myc and Pim proto-oncogenes by Jak2V617F was found to be FERM domain dependent. An inducible constitutively active STAT5 mutant expressed in BaF3 cells was sufficient to induce Myc and Pim. Finally, the FERM domain in Jak2V617F was also required for abnormal hematopoiesis in transduced primary murine fetal liver cells. Overall, our results suggest that constitutive activation of Jak2 requires an intact FERM domain for a transforming phenotype, and is necessary for activation of the major target of Jak2, STAT5.Keywords
This publication has 46 references indexed in Scilit:
- Two Domains of the Erythropoietin Receptor Are Sufficient for Jak2 Binding/Activation and FunctionMolecular and Cellular Biology, 2006
- JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation modelBlood, 2006
- Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2The EMBO Journal, 2006
- Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1)The International Journal of Cell Cloning, 2006
- Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and StabilityJournal of Biological Chemistry, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF‐E2British Journal of Haematology, 2005
- c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosisOncogene, 2002
- Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cellsOncogene, 2002